DocWire News Editors

DocwireNews

Risk assessment scores were effective at predicting <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/evolocumab-lower-cardiovascular-events/">cardiovascular</a> and ischemic endpoints such as mortality, a new analysis in <a href="https://www.atherosclerosis-journal.com/article/S0021-9150(20)31570-7/fulltext">Atherosclerosis</a> suggests.&ldquo;Thromboischemic and bleeding events are rare but life-threatening complications after percutaneous coronary intervention (PCI),&rdquo; the authors wrote. &ldquo;Various risk assessment models have been established to predict short- and long-term adverse events in patients with chronic and acute coronary syndromes.&rdquo;The researchers, looking to compare available risk assessment systems on their ability to identify high-risk patients with symptomatic coronary artery disease (CAD) included more than 1,500 consecutive patients (n=1,565) with symptomatic CAD (821 patients with chronic disease and 744 with acute) and were followed-up for endpoints at one, three and five years. Endpoints included all-cause death, myocardial infarction (MI), ischemic stroke (IS), and bleeding. The authors calculated the CALIVER, DAPT, GRACE 2.0, PARIS-CTE, PARIS-MB, PRECISE DAPT, and PREDICT-STABLE scores for all groups. The primary study endpoint was a combined ischemic endpoint of all-cause death, MI, and/or ischemic stroke, with secondary endpoints defined as single occurrence of either all-cause death, MI, ischemic stroke, or bleeding.According to the study results, the GRACE 2.0 score demonstrated good discrimination performance for predicting the combined ischemic endpoint at three and five year follow-up. Additionally, CALIBER, GRACE 2.0, and PARIS-CTE all performed best at predicting all-cause death throughout follow-up. PARIS-CTE and CALIBER best predicted ischemic stroke. None of the scores, however, did well at predicting MI or bleeding.&ldquo;CALIBER, GRACE 2.0, PARIS-MB and PRECISE-DAPT scores showed good performance in predicting all-cause death at one, three, and five years follow-up,&rdquo; the authors wrote. &ldquo;Combined ischemic endpoint (all-cause death, myocardial infarction and/or ischemic stroke) was best predicted by GRACE 2.0 score. None of the investigated scores could efficiently predict MI or bleeding complications in short- and long-term follow-up.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Predicting 1-, 3- and 5-year outcomes in patients with coronary artery&hellip; <a href="https://t.co/bbDjs9d2St">https://t.co/bbDjs9d2St</a> <a href="https://t.co/2YRf2vnk8K">pic.twitter.com/2YRf2vnk8K</a>
&mdash; Miguel A. Maria. Medico de Familia (@Miguel_A_Maria) <a href="https://twitter.com/Miguel_A_Maria/status/1338837555291230210?ref_src=twsrc%5Etfw">December 15, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Risk Scores Predict Death, Stroke Well, But Not MI or Bleeding

Atherosclerotic Disease

Risk assessment scores were effective at predicting cardiovascular and ischemic endpoints such as mortality, a new analysis in Atherosclerosis suggests. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe